Business as usual - not!

If Genmab A/S were based in the U.S., activist investors would be demanding seats on the board and a say in the choice of a new CEO following last week's abrupt announcement that co-founder, President and CEO Lisa Drakeman was gone.

That might happen yet, as 8% of the company's shares are held by U.S. investors, while Hendrikus Hubertus Franciscus Stienstra, partly through Mercurius Beleggingsmaatschappij B.V. and Stimex Participatiemaatschappij B.V., own 10% of the company...